TREATMENT OF EARLY AGE MANIA (TEAM)

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。TEAM研究的目的是评估三种不同药物对6至15.11岁儿童和青少年躁狂症的有效性。躁狂症是一个术语，用于描述一种疾病，其中儿童可能感觉很好或易怒，导致损害其功能的行为。三种研究药物为锂、丙戊酸盐和利培酮。研究描述团队研究分为3个部分。贸易效率评估方法研究的第一部分是基线评估。第二部分是药物治疗评估（8-16周）。最后是6个月的随访评估。因此，本研究将需要长达10个月的时间才能完成。研究药物为利培酮（商品名Risperdal）、锂（商品名Eskalith）和丙戊酸盐（商品名Depakote）。这些研究药物已被批准用于成人躁狂症，但尚未被FDA测试或批准用于治疗儿童或青少年躁狂症。大约有110名受试者将在约翰霍普金斯参加。美国将有多达540例受试者参与本研究。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. PURPOSE OF THE STUDY The purpose of the TEAM study is to evaluate the usefulness of three different medicines for children and teenagers ages 6 to 15.11 with mania. Mania is a term used to describe an illness in which children may feel so good or irritable leading to behavior that impairs their functioning. The three study medications are lithium, valproate, and risperidone. DESCRIPTION OF THE STUDY There are 3 parts to the TEAM study. The first part of the TEAM study is a baseline assessment. The second part is the medication treatment evaluation (8-16 weeks long). The last part is a 6-month follow-up assessment. Therefore, this study will take up to 10 months to complete. The study medications are risperidone (trade name Risperdal), lithium (trade name Eskalith), and valproate (trade name Depakote). These study medications are approved for use in adults with mania, but they have not yet been tested or approved by the FDA for treatment of mania in children or adolescents. There will be approximately 110 subjects participating here at Johns Hopkins. There will be up to 540 subjects participating in this study across the U.S.A.